Felicity Thomas

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Leveraging automation advancements can help improve efficiency in aseptic processing and speed up commercialization of critical drug products.

Pharm Tech Group looks at the challenges surrounding the development and manufacture of ATMPs in more detail with Agne Vaitkeviciene, CEO of Memel Biotech.

Pharm Tech Group sits down with Bernard Sagaert, CEO of etherna, to examine the role of mRNA in the treatment of autoimmune diseases.

The political landscapes of both the EU and UK are set to change after the latest elections, which could affect the bio/pharma industry.

Pharm Tech Group chats with Dr. Monika Paulė, CEO and co-founder of Caszyme about the evolution of CRISPR.

Sterling is strengthening its development and manufacturing services for ADCs with a dedicated GMP suite at its Wisconsin facility.

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

A greater understanding of molecular and cellular biology and technological advancements are revolutionizing the field of biologics.

Pharmaceutical company, Nanomerics, and several companies that work with the pharmaceutical industry have been recognized by King Charles III for business achievements.

FDA has granted approval for the use of Novartis’ radioligand therapy, Lutathera, to treat pediatric patients with gastroenteropancreatic neuroendocrine tumors.

In this exclusive Drug Digest video interview, Felicity Thomas, Europe/senior editor, Pharmaceutical Technology Group, interviews Dr. Krizia M. Karry, Global Head of Technical Marketing for BASF Pharma Solutions, on the topic of hot melt extrusion.

In this latest installment of the Europa Perspectives series, Alexander Natz, Secretary General at EUCOPE, delves into the European Commission’s new measures aimed at making lifecycle management more efficient across the European Union.

Our Future Health, a health research program in the UK, has welcomed Novartis as a new industry partner.

Plans to update the European Union’s variation framework have been finalized.

A revised regulatory variation framework should make lifecycle management more efficient in Europe.

More synthetic opioids have been placed under the strictest controls in the United Kingdom.

New plans laid out by AstraZeneca will see £650 million ($828 million) be invested into the UK.

The power of collaboration is a critically important for the bio/pharma industry.

Given the criticality of fill/finish processes, it is clear that automation is the next technological step.

Wider life sciences industries in the UK and Europe are receiving favourable financial support from governing bodies.

AstraZeneca has completed its acquisition of Icosavax, gaining the IVX-A12 vaccine candidate that targets RSV and hMPV.

GSK is expanding its respiratory biologics portfolio with its acquisition of Aiolos Bio and its novel therapy, AIO-001.

NICE has recommended the use of AbbVie's Tepkinly as a treatment option for eligible adults with diffuse large B-cell lymphoma.

ProductLife Group has announced its acquisition of Australian company Commercial Eyes.

The industry’s M&A activity is on the up and expected to continue to rise in 2024.

Agilent Technologies and Incyte have signed an agreement to collaborate on the development of companion diagnostics programs.

In this exclusive Drug Digest video interview, Felicity Thomas, Europe/senior editor, Pharmaceutical Technology Group, interviews an esteemed panel of experts from IPEC Americas about excipient grades.

IMU Biosciences has secured £11.5 million in its Series A financing round.

Getinge has announced the inauguration of its new Global Centre of Excellence for Chemistry in the United Kingdom